Coherus Biosciences Divests UDENYCA Business

Tip Ranks
2025.11.13 22:36
portai
I'm PortAI, I can summarize articles.

Coherus Biosciences has divested its UDENYCA business, marking a significant shift in its strategy by focusing on its innovative oncology pipeline and expanding LOQTORZI sales. This divestiture includes the UDENYCA, YUSIMRY, and CIMERLI franchises, now classified as discontinued operations. The latest analyst rating for Coherus Biosciences stock is a Hold with a $1.50 price target, reflecting financial challenges and bearish momentum despite some positive strategic initiatives.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

An update from Coherus Biosciences ( (CHRS) ) is now available.

On April 11, 2025, Coherus Biosciences sold its UDENYCA business, marking a significant divestiture of its biosimilar businesses, which included the UDENYCA, YUSIMRY, and CIMERLI franchises. This strategic shift led to the reclassification of these businesses as discontinued operations in their financial reports, reflecting a focus on their innovative oncology pipeline and the expansion of LOQTORZI sales.

The most recent analyst rating on (CHRS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Spark’s Take on CHRS Stock

According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.

Coherus Biosciences faces significant financial and valuation challenges, with declining revenues and a negative P/E ratio. Technical indicators suggest bearish momentum. However, the earnings call provided some positive insights into strategic initiatives and financial improvements, slightly offsetting the negative aspects.

To see Spark’s full report on CHRS stock, click here.

More about Coherus Biosciences

Coherus Biosciences is a fully integrated commercial-stage oncology company with a focus on innovative cancer treatments. The company has an approved PD-1 inhibitor, LOQTORZI, and is developing additional clinical candidates targeting various cancers such as liver, lung, and head and neck cancers.

Average Trading Volume: 1,285,744

Technical Sentiment Signal: Hold

Current Market Cap: $164.4M

Learn more about CHRS stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer